Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian District, Beijing 100142, China.
Department of Oncology, Affiliated Hospital of Guiyang Medical College, Guizhou Cancer Hospital, No.1 Beijing West Road, Yunyan District, Guiyang 550003, China.
Cancer Cell Int. 2014 Mar 13;14(1):25. doi: 10.1186/1475-2867-14-25.
Rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL). Inactivation of phosphorylation of STAT3 plays an essential role in rituximab-induced anti-proliferative activity in B-cell lymphoma. However, the relationship between STAT3 genetic polymorphisms and clinical response to standard frontline treatment with rituximab has not been well illustrated yet.
In this study we analyzed the STAT3 polymorphisms and prognosis of 166 diffuse large B-cell lymphoma (DLBCL) patients who were treated with rituximab from 2007 to 2010. Determination of the STAT3 polymorphisms of rs2293152 from genomic DNA was achieved by Sanger chain termination sequencing.
We did not observe obvious correlation between patients' disease features and STAT3 polymorphisms, but patients with homozygous genotypes at rs2293162 showed a trend of higher CR rate than those with the heterozygous genotype, especially in non-GCB subgroup (p = 0.011). Furthermore, homozygous genotypes GG and CC also showed advantages of long-term survival compared with heterozygous genotype patients (p = 0.022).
These results suggest that STAT3 polymorphisms could be a suitable biomarker related to clinical outcome of DLBCL patients treated with rituximab.
利妥昔单抗联合 CHOP 化疗已广泛用于多种 B 细胞非霍奇金淋巴瘤（B-NHL）的标准治疗。STAT3 磷酸化失活在利妥昔单抗诱导的 B 细胞淋巴瘤抗增殖活性中起重要作用。然而，STAT3 基因多态性与利妥昔单抗标准一线治疗的临床反应之间的关系尚未得到很好的阐明。
本研究分析了 2007 年至 2010 年间接受利妥昔单抗治疗的 166 例弥漫性大 B 细胞淋巴瘤（DLBCL）患者的 STAT3 多态性和预后。通过 Sanger 链终止测序确定来自基因组 DNA 的 STAT3 多态性 rs2293152。
我们没有观察到患者疾病特征与 STAT3 多态性之间存在明显相关性，但 rs2293162 纯合基因型患者的 CR 率高于杂合基因型患者，尤其是在非 GCB 亚组（p=0.011）。此外，与杂合基因型患者相比，纯合基因型 GG 和 CC 也显示出长期生存的优势（p=0.022）。
这些结果表明，STAT3 多态性可能是与接受利妥昔单抗治疗的 DLBCL 患者临床结局相关的合适生物标志物。
